AI Monitoring Slashes COPD and Asthma Hospitalizations by Half in Major Study
Finn's Take· TL;DR- AI monitoring detected early warning signs between doctor visits, reducing hospitalizations by 50 percent and total care costs by 57 percent.
- The system acts as a proactive health coach, tracking lung function, medication adherence, and environmental triggers to prevent disease exacerbations before they occur.
- Intermountain Health plans to scale the successful iCARE technology across its 34-hospital network serving six Western states if results continue to hold.
A Silent Crisis Between Doctor Visits
For the millions of Americans living with chronic lung disease, the most dangerous moments don't happen in a hospital room. They happen at home — quietly, invisibly — in the weeks or months between medical appointments. Researchers say the most concerning moments for doctors treating patients with chronic lung disease are not hospitalizations. It's the silence between patient visits — weeks or months in which risk accumulates invisibly, unmonitored, until the next crisis arrives. A sweeping new study out of Intermountain Health suggests that artificial intelligence may finally be able to fill that dangerous gap.
COPD and asthma are two of the most common chronic respiratory conditions in the world, costing more than $50 billion to treat per year in the United States — much of it spent on hospitalizations that could be prevented. COPD alone affects one out of every 13 adults in the United States. The scale of the problem is enormous, and for years, the medical community has struggled to get ahead of it.
What the iCARE Study Found
The iCARE study — short for Intermountain COPD and Adult Asthma Remote Evaluation — was a 24-month clinical program at Intermountain Health, one of the largest integrated health systems in the U.S. The study tested whether AI-powered continuous monitoring, combined with human care teams, could shift respiratory care from reactive to predictive, catching exacerbations before they happen.
The study documented 1,200 patients at five Intermountain Health hospitals in Utah over a two-year period to observe what happens when a health system is proactive and intervenes to prevent patients from deteriorating and supports them at home — helping them learn to better manage their health, while also watching for the signals that precede deterioration. The results were striking. Continuous, AI-driven monitoring of patients resulted in a reduced total cost of care by 57 percent, hospitalizations by 50 percent, and emergency department visits by 20 percent.
How the Technology Actually Works
The iCARE study operated on a tiered intervention logic. CareCentra's AI serves as the first line of response — detecting early signals of risk and deploying nudge theory to shape patient behavior before the situation escalates. Think of it less like a robot doctor and more like a highly attentive health coach that never sleeps. When a patient's lung function drops beyond a certain threshold, the system engages to improve inhaler technique and ensure medication adherence. When missed doses accumulate, it addresses adherence barriers. When environmental triggers spike, it warns patients in real time and suggests behavioral actions to reduce risks.
CareCentra CEO Vasant Kumar described it as "a smart check-engine light" — an AI-driven health maintenance and early warning system designed to keep patients healthier and out of the hospital, sensing rising risks between clinic visits and facilitating intervention before an exacerbation occurs. The study's principal investigator, Peter Crossno, MD, senior medical director of respiratory care at Intermountain Health, said the technology "allows us to move from reactive care to proactive care for these patients."
What Comes Next
Results of the iCARE study were presented by Intermountain Health researchers at the American Thoracic Society 2026 International Conference in Orlando, Florida. The reception from the medical community underscored just how significant the findings are. For a field that has long been constrained by the limitations of episodic, appointment-driven care, continuous AI monitoring represents a fundamental shift in how chronic disease management can work.
Intermountain Health is now considering ways to scale the iCARE technology across its network of 34 hospitals and 400 clinics — a system serving patients across Utah, Idaho, Colorado, Wyoming, Montana, and Nevada. If those results hold at scale, the implications stretch far beyond the Mountain West. With tens of millions of COPD and asthma patients across the country, a model that cuts hospitalizations in half could reshape how America manages chronic respiratory disease — and dramatically reduce the human and financial toll it takes every year.